New obesity drug HDM1005 put to the test: will it play nice with other meds?

NCT ID NCT07502001

Not yet recruiting Knowledge-focused Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage study will test an experimental drug called HDM1005 in 42 overweight or obese adults. Researchers want to see how HDM1005 affects stomach emptying and whether it changes how the body processes common medications like metformin, atorvastatin, warfarin, and digoxin. Participants will receive HDM1005 injections along with single doses of these other drugs to measure safety and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HDM1005 injection
What this could lead to: If successful, this study could show that HDM1005 is safe to use alongside common medications like metformin and statins in people who are overweight or obese.
What could go wrong: This is a very early Phase 1 trial with only 42 people, so results may not apply to everyone. The study focuses on drug interactions, not weight loss or health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

The Second Affiliated Hospital of Anhui Medical University

Hefei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.